Evidence map›Paper›PMID 37143128›Full record

ArticleTrials2023

A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study.

Rubai Zhou, Huifeng Zhang, Shen He, Yi Li, Guiyun Xu, Jinsong Huang, Huaning Wang, Qian Wang, Biao Li, Xuemei Wang and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04209166 (A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04209166 naunknown statusnot on this map

A Study of Individualized Diagnosis and Treatment for Major Depressive Disorder With Atypical Features

TypeinterventionalSponsorShanghai Mental Health CenterRan2019 to 2022Enrolled780ConditionsMajor Depressive DisorderArmsSSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors), SSRIs/SNRIs+Mood Stabilizer, SSRIs/SNRIs+Quetiapine, Usual Treatment
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Rubai ZhouDivision of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai, 200030, China.
Huifeng ZhangDivision of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai, 200030, China.
Shen HeDivision of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai, 200030, China.
Yi LiWuhan Mental Health Center, Wuhan, Hubei, China.
Guiyun XuDepartment of Affective Disorders, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jinsong HuangDalian Seventh People's Hospital, Dalian, Liaoning, China.
Huaning WangDepartment of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Qian WangSchool of Biomedical Engineering, ShanghaiTech University, Shanghai, China.
Biao LiWuhan Mental Health Center, Wuhan, Hubei, China.
Xuemei WangJianghan University, Wuhan, Hubei, China.
Ningning ChenDepartment of Affective Disorders, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fang LiDalian Seventh People's Hospital, Dalian, Liaoning, China.
Xiaosa LiDepartment of Psychiatry, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Mengjun LiuSchool of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Daihui PengDivision of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai, 200030, China. pdhsh@126.com.
Shanghai Jiao Tong University · CNSeventh People's Hospital of Dalian · CNAir Force Medical University · CNGuangzhou Medical University · CNGuangzhou Psychiatric Hospital · CNJianghan University · CNShanghaiTech University · CNXijing Hospital · CN

Funding

Cross-disciplinary and Translational Medical Research of Shanghai Jiao Tong University ZH2018ZDA29Shanghai Clinical Research Center for Mental Health CRC2018ZD05
6 · The paper itself

Abstract

backgroundMajor depressive disorder (MDD) with atypical features, namely depression with atypical features (AFD), is one of the most common clinical specifiers of MDD, closely associated with bipolar disorder (BD). However, there is still a lack of clinical guidelines for the diagnosis, treatment, and prognosis of AFD. Our study mainly focuses on three issues about how to identify AFD, what is the appropriate individualized treatment for AFD, and what are the predictive biomarkers of conversion to BD.

methodsThe Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD) is a multicenter, prospective, open-label study consisting of a 12-week randomized controlled trial (RCT) and a continued follow-up until 4 years or reaching the study endpoint. It is enrolling 480 patients with AFD (120 per treatment arm), 100 patients with BD, and 100 healthy controls (HC). Multivariate dimension information is collected including clinical features, cognitive function, kynurenine pathway metabolomics, and multimodal magnetic resonance imaging (MRI) data. Firstly, multivariate informatics analyses are performed to recognize patients with AFD from participants including the first-episode and recurrent atypical depression, patients with BD, and patients with HC. Secondly, patients with atypical depression are randomly allocated to one of the four treatment groups including "single application of selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI)", "SSRI/SNRI combined with mood stabilizer," "SSRI/SNRI combined with quetiapine (≥ 150 mg/day)," or "treatment as usual (TAU)" and then followed up 12 weeks to find out the optimized treatment strategies. Thirdly, patients with atypical depression are followed up until 4 years or switching to BD, to explore the risk factors of conversion from atypical depression to BD and eventually build the risk warning model of conversion to BD. DISCUSSION: The first enrolment was in August 2019. The iDoT-AFD study explores the clinical and biological markers for the diagnosis, treatment, and prognosis of AFD and further provides evidence for clinical guidelines of AFD.

trial registrationClinicalTrials.gov NCT04209166. Registered on December 19, 2019.

Indexed as

Major Depressive DisorderSerotonin and Noradrenaline Reuptake InhibitorsDepressionHumansMulticenter Studies as TopicPrognosisRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsAtypical featuresIndividualized diagnosis and treatmentMajor depressive disorderPredictive biomarkers of conversion to bipolar disorder

Identifiers

PMID37143128
PMCPMC10161548
OpenAlexW4368364267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.